文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

溶血抑制B细胞体液免疫并调节镰状细胞病同种免疫风险

Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease.
PubMed 文献 · Blood · 2021-01-01

研究探讨镰状细胞病(SCD)中血管内溶血对B细胞体液免疫及同种免疫风险的影响。发现游离血红素通过抑制DOCK8/STAT3通路及上调HO-1(经CO和胆绿素)抑制B细胞分化,而未同种免疫患者B细胞对血红素敏感,已同种免疫者不敏感。奎宁在血红素存在下经HO-1诱导抑制B细胞,可逆转同种免疫患者的抵抗。

要点

  • 游离血红素抑制人B细胞向浆母细胞和浆细胞分化。
  • 已同种免疫SCD患者B细胞对血红素抑制不敏感。
  • 奎宁依赖血红素和HO-1诱导抑制B细胞活性。

核心结论

  • 溶血可抑制B细胞体液免疫,B细胞对血红素的反应性可能是SCD同种免疫风险的决定因素。
  • 奎宁通过恢复B细胞血红素敏感性,可能具有预防和抑制SCD患者同种免疫的治疗潜力。

研究设计与样本

  • 研究对比非同种免疫与同种免疫SCD患者的B细胞对血红素的反应。
  • 体外实验分析血红素对B细胞分化的影响及信号通路。
  • 筛选血红素结合分子并鉴定奎宁对B细胞活性的抑制作用。

主要发现

  • 细胞游离血红素通过抑制DOCK8/STAT3信号通路及上调HO-1(经CO和胆绿素)抑制B细胞浆母细胞和浆细胞分化。
  • 非同种免疫SCD患者B细胞被外源血红素抑制,而同种免疫组B细胞对血红素抑制无反应并易分化为浆细胞。
  • 非同种免疫组较同种免疫组B细胞基础DOCK8水平升高,且HO-1介导的活化B细胞抑制更强。
  • 奎宁仅在血红素存在下通过HO-1诱导抑制B细胞,逆转同种免疫患者的血红素抑制抵抗。

临床怎么用

  • B细胞血红素反应性可能作为SCD同种免疫风险评估的参考指标。
  • 奎宁可能用于预防和抑制SCD患者同种免疫,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Red blood cell alloimmunization remains a barrier for safe and effective transfusions in sickle cell disease (SCD), but the associated risk factors remain largely unknown. Intravascular hemolysis, a hallmark of SCD, results in the release of heme with potent immunomodulatory activity, although its effect on SCD humoral response, specifically alloimmunization, remains unclear. Here, we found that cell-free heme suppresses human B-cell plasmablast and plasma cell differentiation by inhibiting the DOCK8/STAT3 signaling pathway, which is critical for B-cell activation, as well as by upregulating heme oxygenase 1 (HO-1) through its enzymatic byproducts, carbon monoxide and biliverdin. Whereas nonalloimmunized SCD B cells were inhibited by exogenous heme, B cells from the alloimmunized group were nonresponsive to heme inhibition and readily differentiated into plasma cells. Consistent with a differential B-cell response to hemolysis, we found elevated B-cell basal levels of DOCK8 and higher HO-1-mediated inhibition of activated B cells in nonalloimmunized compared with alloimmunized SCD patients. To overcome the alloimmunized B-cell heme insensitivity, we screened several heme-binding molecules and identified quinine as a potent inhibitor of B-cell activity, reversing the resistance to heme suppression in alloimmunized patients. B-cell inhibition by quinine occurred only in the presence of heme and through HO-1 induction. Altogether, these data suggest that hemolysis can dampen the humoral B-cell response and that B-cell heme responsiveness maybe a determinant of alloimmunization risk in SCD. By restoring B-cell heme sensitivity, quinine may have therapeutic potential to prevent and inhibit alloimmunization in SCD patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pal M, Bao W, Wang R, et al. Hemolysis inhibits humoral B-cell responses and modulates alloimmunization risk in patients with sickle cell disease. Blood. 2021. PMID: 33152749. doi:10.1182/blood.2020008511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。